World Library  
Flag as Inappropriate
Email this Article

Phosphoinositide 3-kinase inhibitor

Article Id: WHEBN0025303574
Reproduction Date:

Title: Phosphoinositide 3-kinase inhibitor  
Author: World Heritage Encyclopedia
Language: English
Subject: Idelalisib, Class I PI 3-kinases, Drug discovery, Chemotherapy, Cell-cycle nonspecific antineoplastic agents
Collection: Drug Discovery, Ec 2.7.1, Experimental Cancer Drugs, Phosphoinositide 3-Kinase Inhibitors
Publisher: World Heritage Encyclopedia

Phosphoinositide 3-kinase inhibitor

The PI3K/AKT/mTOR pathway is an important signalling pathway for many cellular functions such as growth control, metabolism and translation initiation. Within this pathway there are many valuable anti-cancer drug treatment targets and for this reason it has been subject to a lot of research in recent years.[1] A Phosphoinositide 3-kinase inhibitor (PI3K inhibitor) is a potential medical drug that functions by inhibiting a Phosphoinositide 3-kinase enzyme which is part of this pathway and therefore, through inhibition, often results in tumour suppression.[2][3]

There are a number of different classes and isoforms of PI3Ks.[4] Class 1 PI3Ks have a catalytic subunit known as p110, with four types (isoforms) - p110 alpha, p110 beta, p110 gamma and p110 delta.[5] The inhibitors being studied inhibit one or more isoforms of the class I PI3Ks.[6][7]

They are being actively investigated for treatment of various cancers.[8][9] [10]

They are also being considered for Inflammatory respiratory disease.[4][6]


  • Notable examples 1
  • Clinical development 2
    • Late stage 2.1
    • Early stage 2.2
  • See also 3
  • References 4
  • Further reading 5
  • External links 6

Notable examples

Clinical development

Late stage

In phase III clinical trials:

In/starting phase II clinical trials:

  • PX-866[13][14][15] In 2010 Starting 4 phase II trials for solid tumours.[16][17]
  • IPI-145, a novel inhibitor of PI3K delta and gamma,[18] especially for hematologic malignancies (currently in two Phase 1 clinical trials in hematologic cancers as well as a broad range of inflammatory conditions).[19] July 2012 the phase I trial was expanded and two phase II trials are planned,[20] OK at 75 mg BID, will try 100 mg BID.[21] Also in phase 2a for asthma.[21]
  • BAY 80-6946, predominantly inhibits PI3Kα,δ isoforms.[22]

Early stage

In early stage clinical trials [10]

  • BEZ235[23] The first into clinical trials, in 2006.[24] A PI3K/mTOR dual inhibitor.[25]
  • RP6530, Dual PI3K delta/gamma inhibitor for lymphomas.[26]
  • TGR 1202, oral PI3K delta inhibitor (previously known as RP5264). Phase I recruiting [27]
  • SF1126[28][29][30] Some early clinical data has been presented.[31][32][33] First PI3KI 'Orphan Drug' for B-cell chronic lymphocytic leukemia (CLL).[34]
  • INK1117, a PI3K-alpha inhibitor in phase I.[35]
  • GDC-0941[36][37][38] IC50 of 3nM.
  • BKM120[39][40]
  • XL147 (also known as SAR245408)[41]
  • XL765 (also known as SAR245409)[42]
  • Palomid 529[43]
  • GSK1059615 The phase I trial of this drug was terminated due to lack of sufficient exposure following single- and repeat- dosing.[44]
  • ZSTK474,[45] a potent inhibitor against p110a.
  • PWT33597, a dual PI3K-alpha/mTOR inhibitor - for advanced solid tumors.[46] IND mid 2011.[47] Phase I recruiting.[48]


  • IC87114[6] a selective inhibitor of p110δ. It has an IC50 of 100 nM for inhibition of p110-δ.
  • TG100–115, inhibits all four isoforms but has a 5-10 fold better potency against p110-γ and p110-δ.
  • CAL263[49]
  • RP6503,Dual PI3K delta/gamma inhibitor for the treatment of Asthma and COPD (Late pre-clinical stage).,[50][51]
  • PI-103[52] Dual PI3K-mTOR inhibitor.[53]
  • GNE-477 is PI3K-alpha and mTOR inhibitor with IC50 values of 4nM and 21nM.
  • CUDC-907, Also an HDAC inhibitor.[54] IND has been filed.[55]
  • AEZS-136, also inhibits Erk1/2.[56]

See also


  1. ^ Kurtz J.E. Ray-Coquard I., 2012. PI3 kinase inhibitors in the clinic: an update. [Review]. Anticancer Research, 32(7), pp.2463-70
  2. ^ [ "PI3K inhibitors: Targeting multiple tumor progression pathways"]. 2003. 
  3. ^ Neri, LM; Borgatti, P; Tazzari, PL; Bortul, R; Cappellini, A; Tabellini, G; Bellacosa, A; Capitani, S; Martelli, AM (2003). "The phosphoinositide 3-kinase/AKT1 pathway involvement in drug and all-trans-retinoic acid resistance of leukemia cells". Molecular cancer research : MCR 1 (3): 234–46.  
  4. ^ a b Ito, K; Caramori, G; Adcock, IM (2007). "Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease". The Journal of Pharmacology and Experimental Therapeutics 321 (1): 1–8.  
  5. ^ Study results provide rationale for use of PI3K inhibitors in therapeutic settings. Retrieved on 2010-11-05.
  6. ^ a b c d Crabbe, T (2007). "Exploring the potential of PI3K inhibitors for inflammation and cancer". Biochemical Society transactions 35 (Pt 2): 253–6.  
  7. ^ Stein, R. (2001). "Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment". Endocrine Related Cancer 8 (3): 237–48.  
  8. ^ Flanagan (Dec 2008). "Zeroing in on PI3K Pathway". 
  9. ^ Wu, P; Liu, T; Hu, Y (2009). "PI3K inhibitors for cancer therapy: what has been achieved so far?". Current medicinal chemistry 16 (8): 916–30.  
  10. ^ a b Maira, Sauveur-Michel; Stauffer, Frédéric; Schnell, Christian; García-Echeverría, Carlos (2009). "PI3K inhibitors for cancer treatment: where do we stand?". Biochemical Society Transactions 37 (Pt 1): 265–72.  
  11. ^ Search results
  12. ^ Wu, M.; Akinleye, A.; Zhu, X. (2013). "Novel agents for chronic lymphocytic leukemia". Journal of Hematology & Oncology 6: 36.  
  13. ^ Howes, AL; Chiang, GG; Lang, ES; Ho, CB; Powis, G; Vuori, K; Abraham, RT (2007). "The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures". Molecular cancer therapeutics 6 (9): 2505–14.  
  14. ^ PX-866 June 2010
  15. ^ NCT00726583 Phase I Trial of Oral PX-866
  16. ^ "ONTY Starts Four-Phase II Trial Program With Its Oral PI3K Inhibitor". 4 Nov 2010. 
  17. ^
  18. ^ "Infinity Initiates Two Phase 1 Trials of IPI-145, a Potent Inhibitor of PI3K Delta and Gamma". 31 Oct 2011. 
  19. ^ "Infinity commences two IPI-145 Phase 1 clinical trials for hematologic malignancies". Retrieved November 28, 2011. 
  20. ^ "Infinity Regains Worldwide Rights to PI3K, FAAH and Early Discovery Programs". 18 July 2012. 
  21. ^ a b Infinity Reports IPI-145 Phase 1 Data Showing Clinical Activity in B-Cell and T-Cell Malignancies at ASH Annual Meeting. Dec 2012
  22. ^ Bayer to Present New Data on Growing Oncology Pipeline. April 2013
  23. ^ Liu, TJ; Koul, D; Lafortune, T; Tiao, N; Shen, RJ; Maira, SM; Garcia-Echevrria, C; Yung, WK (2009). "NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas". Molecular cancer therapeutics 8 (8): 2204–10.  
  24. ^ NCT00620594 A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
  25. ^ Serra, V; Markman, B; Scaltriti, M; Eichhorn, PJA; Valero, V; Guzman, M; Botero, ML; Llonch, E; Atzori, F.; Di Cosimo, S.; Maira, M.; Garcia-Echeverria, C.; Parra, J. L.; Arribas, J.; Baselga, J. (2008). "NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations". Cancer Research 68 (19): 8022–30.  
  26. ^
  27. ^
  28. ^ Definition of pan-PI3K/mTOR inhibitor SF1126 - National Cancer Institute Drug Dictionary. Retrieved on 2010-11-05.
  29. ^ "Semafore's PI3 Kinase Inhibitor SF1126 Is A Vascular Targeted Conjugate In Phase I Clinical Trials In Solid Tumors And Multiple Myeloma" (Press release). Semafore Pharmaceuticals. April 15, 2008. Retrieved November 3, 2010. 
  30. ^ NCT00907205 A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors (SF112600106)
  31. ^ Semafore's SF1126 peptidic prodrug demonstrates clinical activity in chronic lymphocytic leukemia. Retrieved on 2010-11-05.
  32. ^ Update on the Novel Prodrug Dual mTOR‐PI3K Inhibitor SF1126
  33. ^
  34. ^ "Semafore Pharmaceuticals Receives FDA Orphan Drug Designation for SF1126 in the Treatment of Chronic Lymphocytic Leukemia". 9 Nov 2010. 
  35. ^ "Intellikine commences INK1117 Phase I dose escalation study in cancer". 12 Oct 2011. 
  36. ^ NCT00974584 A Study of the Safety and Pharmacology of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel and Carboplatin With or Without Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
  37. ^ NCT00876109
  38. ^ NCT00876122 A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable
  39. ^ NCT01068483
  40. ^ NCT01132664
  41. ^ NCT01042925
  42. ^ NCT00485719
  43. ^ NCT01033721
  44. ^ "GSK Clinical Register: PIK111051". 
  45. ^ A Safety Study of Oral ZSTK474 in Patients With Cancer
  46. ^ Pathway Receives $7.5M Boost to Take Lead PI3K/mTOR Inhibitor into Clinical Development. 25 May 2011
  47. ^
  48. ^
  49. ^ Study to Investigate Effects of CAL-263 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber
  50. ^'13.pdf
  51. ^
  52. ^ Werzowa et al. (4 Nov 2010). "Vertical Inhibition of the mTORC1/mTORC2/PI3K Pathway Shows Synergistic Effects against Melanoma In Vitro and In Vivo". Journal of Investigative Dermatology 131 (2): 495–503.  
  53. ^ Fan et al. (Nov 2010). "Akt and Autophagy Cooperate to Promote Survival of Drug-Resistant Glioma".  
  54. ^
  55. ^
  56. ^

Further reading

  • Williams, Roger; Berndt, Alex; Miller, Simon; Hon, Wai-Ching; Zhang, Xuxiao (2009). "Form and flexibility in phosphoinositide 3-kinases". Biochemical Society Transactions 37 (Pt 4): 615–626.  

External links

  • Novartis on BEZ235 and BKM120 PI3K inhibitors
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.